Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids
- Conditions
- Asthma
- Interventions
- Drug: Placebo matching RespimatDrug: BI 54903 MDDrug: BI 54903 HD
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT01458912
Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.
- First Posted Date
- 2011-10-14
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT01451775
- Locations
- 🇩🇪
1245.79.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Dabigatran Etexilate in Patients With Mechanical Heart Valves
- Conditions
- Heart Valve Diseases
- Interventions
- First Posted Date
- 2011-10-14
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 328
- Registration Number
- NCT01452347
- Locations
- 🇧🇪
1160.113.32005 Boehringer Ingelheim Investigational Site, Gent, Belgium
🇨🇿1160.113.42001 Boehringer Ingelheim Investigational Site, Prague 5, Czech Republic
🇧🇪1160.113.32007 Boehringer Ingelheim Investigational Site, Brussel, Belgium
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
- Conditions
- Breast NeoplasmsNeoplasm Metastasis
- Interventions
- First Posted Date
- 2011-09-27
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 121
- Registration Number
- NCT01441596
- Locations
- 🇰🇷
1200.67.82002 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
🇺🇸1200.67.10105 Boehringer Ingelheim Investigational Site, Fullerton, California, United States
🇺🇸1200.67.10108 Boehringer Ingelheim Investigational Site, Santa Barbara, California, United States
Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2011-09-22
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 689
- Registration Number
- NCT01438814
- Locations
- 🇧🇪
1218.60.32001 Boehringer Ingelheim Investigational Site, Genk, Belgium
🇧🇪1218.60.32005 Boehringer Ingelheim Investigational Site, Ham, Belgium
🇧🇪1218.60.32004 Boehringer Ingelheim Investigational Site, Natoye, Belgium
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2011-09-09
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2624
- Registration Number
- NCT01431274
- Locations
- 🇺🇸
1237.5.01028 Boehringer Ingelheim Investigational Site, Columbia, Maryland, United States
🇨🇿1237.5.42005 Boehringer Ingelheim Investigational Site, Rokycany, Czech Republic
🇫🇮1237.5.35802 Boehringer Ingelheim Investigational Site, Turku, Finland
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2011-09-09
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2539
- Registration Number
- NCT01431287
- Locations
- 🇸🇰
1237.6.42106 Boehringer Ingelheim Investigational Site, Zilina, Slovakia
🇿🇦1237.6.27002 Boehringer Ingelheim Investigational Site, Bellville, South Africa
🇺🇸1237.6.01129 Boehringer Ingelheim Investigational Site, Henderson, Nevada, United States
GLORIA-AF Registry Program (Phase I)
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2014-03-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1096
- Registration Number
- NCT01428765
- Locations
- 🇭🇷
1160.114.04001 Boehringer Ingelheim Investigational Site, Opatija, Croatia
🇳🇱1160.114.31008 Boehringer Ingelheim Investigational Site, Enschede, Netherlands
🇨🇳1160.114.08017 Boehringer Ingelheim Investigational Site, Beijing, China
Olodaterol Bridging Study in Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2011-11-22
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT01428622
- Locations
- 🇫🇷
1249.7.33003 Boehringer Ingelheim Investigational Site, Gières, France
Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects
- First Posted Date
- 2011-09-01
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT01426958
- Locations
- 🇩🇪
1200.151.1 Boehringer Ingelheim Investigational Site, Biberach, Germany